Esther Duperchy

Esther Duperchy has extensive experience in the field of microbiology and anti-infectives research. Esther is currently serving as the Director of Translational R&D at Aurobac Therapeutics since 2023. Prior to that, they worked at Summit Therapeutics, where they held various roles, including Director of Microbiology and Oncology Research and Associate Director of Anti-Infectives Research.

During their time at Summit Therapeutics, Duperchy played a key role in the development of Ridinilazole, a microbiome-sparing antibiotic for the treatment of Clostridioides difficile infection. Esther led Phase 3 microbiology, microbiome, and bile acid analyses and also co-led pre-clinical microbiology and mechanism of action studies. Esther managed vendors, prepared regulatory documents, and presented data to senior management.

Before joining Summit Therapeutics, Duperchy worked at Cantab Biopharmaceuticals/Cantab Anti-Infectives as a Senior Biologist, where they participated in anti-infectives drug discovery at the preclinical stage. Esther also worked at Novacta Biosystems as a Research Scientist and Senior Scientist, focusing on the in vitro biosynthesis of mersacidin, a peptide antibiotic.

Duperchy began their career as a Postdoctoral Researcher at the University of Oxford, where they conducted research in their field of expertise.

Esther Duperchy holds a PhD in Molecular Microbiology, which they obtained from Heidelberg University between the years 1999 and 2003. Prior to that, they had completed a Master's degree in Molecular Microbiology from University J Fourier from 1997 to 1998. In addition to their academic accomplishments, they have also obtained several certifications, including Level 3 NVQ Certificate in Management from the Institute of Leadership & Management (ILM) in 2015, Pharmacokinetics for the non-specialist from Informa Life Sciences in 2011, and ICH-GCP from THE FACULTY OF PHARMACEUTICAL MEDICINE OF THE ROYAL COLLEGES OF PHYSICIANS OF THE UNITED KINGDOM.